Patent application number | Description | Published |
20100113500 | ORALLY BIOAVAILABLE PRODUCTS OF (+)-3-HYDROXYMORPHINAN FOR PARKINSON'S DISEASE PREVENTION OR TREATMENT - The present invention is directed to a novel prodrug of (+)-3-hydroxymorphinan compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the same, and its use for preventing or treating Parkinson's disease. | 05-06-2010 |
20110178091 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS - The present invention relates to novel arylpiperazine-containing pyrrole 3-carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof which is useful for preventing or treating depressive disorders. The present invention also provides a method for preparing the arylpiperazine-containing pyrrole 3-carboxamide derivatives or the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating depressive disorders. | 07-21-2011 |
20120064411 | POSITIVE ACTIVE MATERIAL, METHOD OF PREPARING THE SAME, AND LITHIUM BATTERY INCLUDING THE POSITIVE ACTIVE MATERIAL - A positive active material, a method of preparing the same, and a lithium secondary battery including the positive active material. | 03-15-2012 |
20120101051 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME - A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided. | 04-26-2012 |
20120115881 | NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME - A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided. | 05-10-2012 |
20120177994 | CATHODE ACTIVE MATERIAL, CATHODE AND LITHIUM BATTERY INCLUDING CATHODE ACTIVE MATERIAL, AND METHOD OF PREPARING THE CATHODE ACTIVE MATERIAL - A cathode active material including: a lithium manganese oxide of which primary particles has a diameter of 1 μm or more and which has a spinel structure in which an X-ray diffraction (XRD) peak intensity ratio of I(111)/I(311) is 1.0 or more; and a boron element disposed at least one position selected from the group consisting of inside the primary particles and on surfaces of the primary particles. | 07-12-2012 |
20130090298 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same - The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. | 04-11-2013 |
20130108926 | NICKEL COMPOSITE HYDROXIDE FOR A LITHIUM SECONDARY BATTERY, LITHIUM COMPOSITE OXIDE FOR A LITHIUM SECONDARY BATTERY PREPARED USING THE NICKEL COMPOSITE HYDROXIDE, METHODS OF PREPARING THE NICKEL COMPOSITE HYDROXIDE AND LITHIUM COMPOSITE OXIDE, POSITIVE ELECTRODE FOR A LITHIUM SECONDARY BATTERY THAT INCLUDES THE LITHIUM COMPOSITE OXIDE, AND LITHIUM SECONDARY BATTERY INCLUDING THE POSITIVE ELECTRODE | 05-02-2013 |
20130196227 | POSITIVE ELECTRODE, METHOD OF MANUFACTURING THE SAME, AND LITHIUM BATTERY COMPRISING THE POSITIVE ELECTRODE - A positive electrode including a current collector and a positive active material layer formed on the current collector, wherein the positive active material layer includes a positive active material, a conductive agent, and the boron-containing inorganic binder having a network structure; a method of manufacturing the same; and a lithium battery including the positive electrode. | 08-01-2013 |
20130344386 | POSITIVE ACTIVE MATERIAL FOR LITHIUM SECONDARY BATTERY, METHOD OF PREPARING THE SAME, POSITIVE ELECTRODE FOR LITHIUM SECONDARY BATTERY INCLUDING THE POSITIVE ACTIVE MATERIAL, AND LITHIUM SECONDARY BATTERY EMPLOYING THE POSITIVE ELECTRODE - A positive active material for a lithium secondary battery is a compound represented by Formula 1 and is in a form of primary particles having a particle diameter in a range of 80 to 400 nm. Formula 1: Li | 12-26-2013 |
20140038052 | POSITIVE ACTIVE MATERIAL AND POSITIVE ELECTRODE AND LITHIUM BATTERY INCLUDING POSITIVE ACTIVE MATERIAL - A positive active material and a lithium battery including the positive active material. The positive active material includes a large diameter active material and a small diameter active material, wherein the small diameter active material includes a Ni-based lithium-transition metal composite oxide and a coating layer including a Mn-containing compound on at least a portion of the surface thereof. | 02-06-2014 |
20140088079 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS - The present invention relates to a compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The present invention also provides a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound. | 03-27-2014 |
20140213642 | NOVEL C-ARYL ANSA SGLT2 INHIBITORS - Disclosed is a novel C-aryl ansa compound having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. Also provided are a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound. | 07-31-2014 |
20140274918 | METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES - The present invention relates to a method for dual inhibition of sodium-dependent glucose cotransporter 1 (SGLT1) and sodium-dependent glucose cotransporter 2 (SGLT2) present in the intestine and kidney by using the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof: | 09-18-2014 |